CELL INTELLIGENCE · 肿瘤细胞治疗研究

当前对周围血免疫细胞表型在癌症治疗耐药中作用的认识

Current Insights into the Role of Peripheral Blood Immune Cell Phenotypes in Resistance to Cancer Therapies.

胸腺肽α-1 在肿瘤治疗中的作用：免疫调节机制、临床应用及转化前景

Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.

细胞因子诱导的杀伤细胞治疗的转化研究现状：基于 Informa 数据库的分析

Translational landscape of cytokine-induced killer cell therapy: an analysis based on the Informa database.

CCR5+ CD8+ T 细胞与 PD-1 阻断治疗反应不佳相关

CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy.

ROBO1 CAR-NK92 细胞中 Cbl-b 敲除增强其抗肿瘤疗效

Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.

免疫评分及其超越：基于免疫微环境生物标志物在实体瘤中的演变与临床整合

Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours.

PD-1 阻断不会增强癌症患者同种异体树突状细胞疫苗接种后的同种免疫

PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.

这些结果表明，在同种异体人类疫苗接种过程中，PD-1 信号对抗体产生和效应功能的影响有限，提示其在体液免疫中的调节作用比先前认为的更为复杂。

共同 γ 链细胞因子驱动的 CAR-T 细胞优化：机制见解与未来方向

Common gamma chain cytokines-driven optimization of chimeric antigen receptor T cells: Mechanistic insights and future directions.

从单细胞数据推断线粒体克隆选择的层次贝叶斯框架

A hierarchical Bayesian framework for inferring mitochondrial clonal selection from single-cell data.

OGN 在泛癌中的临床效用：诊断生物标志物和免疫微环境调节因子

Clinical utility of OGN in pan-cancer: diagnostic biomarker and immune microenvironment regulator.

我们的泛癌分析强调 OGN 是一种依赖于背景的调节因子，将细胞外基质（ECM）重塑与免疫和血管生成信号联系起来。其在泛癌中的失调、诊断/预后价值以及与免疫逃逸机制的串扰，表明 OGN 是一种有前景的多功能生物标志物和治疗靶点。